Stockscreener 앱 받기
7.21
1.23%
-0.09
시간 외 거래:
7.21
전일 마감가:
$7.30
열려 있는:
$7.3
하루 거래량:
963.05K
Relative Volume:
0.82
시가총액:
$672.07M
수익:
$823.60M
순이익/손실:
$-116.00M
주가수익비율:
-5.5462
EPS:
-1.3
순현금흐름:
$-107.30M
1주 성능:
+1.69%
1개월 성능:
+10.24%
6개월 성능:
+38.92%
1년 성능:
-50.28%
1일 변동 폭
$7.20
$7.395
1주일 범위
$6.99
$7.43
52주 변동 폭
$3.76
$15.47
Myriad Genetics Inc Stock (MYGN) Company Profile
명칭
Myriad Genetics Inc
전화
801-584-3600
주소
322 NORTH 2200 WEST, SALT LAKE CITY, UT
MYGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
7.21 | 680.46M | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
572.28 | 217.50B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
226.33 | 164.13B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
704.20 | 56.49B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
139.68 | 40.44B | 6.95B | 1.30B | 1.15B | 4.5714 |
|
IQV
Iqvia Holdings Inc
|
222.26 | 38.48B | 15.90B | 1.28B | 2.21B | 7.2842 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-21 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-03-12 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | 개시 | Craig Hallum | Buy |
| 2024-12-10 | 개시 | UBS | Neutral |
| 2024-12-09 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-27 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-03 | 재개 | Jefferies | Underperform |
| 2024-05-08 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | 재개 | Piper Sandler | Neutral |
| 2023-12-19 | 개시 | Wells Fargo | Equal Weight |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-07-05 | 재개 | JP Morgan | Underweight |
| 2023-05-23 | 업그레이드 | Goldman | Sell → Buy |
| 2023-01-18 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | 개시 | Stephens | Equal-Weight |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-06-15 | 개시 | Raymond James | Mkt Perform |
| 2021-06-03 | 개시 | Goldman | Sell |
| 2019-09-26 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2019-07-29 | 다운그레이드 | Needham | Strong Buy → Hold |
| 2019-07-09 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2019-03-12 | 재확인 | Needham | Strong Buy |
| 2019-01-03 | 개시 | Needham | Strong Buy |
| 2018-11-30 | 업그레이드 | Goldman | Sell → Neutral |
| 2018-10-10 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | 개시 | Goldman | Sell |
| 2018-01-22 | 재확인 | Barclays | Equal Weight |
| 2018-01-05 | 개시 | BTIG Research | Buy |
| 2017-10-02 | 재개 | Leerink Partners | Mkt Perform |
| 2017-08-09 | 재확인 | Barclays | Equal Weight |
| 2017-02-08 | 업그레이드 | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | 개시 | Deutsche Bank | Sell |
| 2016-10-10 | 다운그레이드 | Ladenburg Thalmann | Neutral → Sell |
모두보기
Myriad Genetics Inc 주식(MYGN)의 최신 뉴스
Myriad Genetics Inc Stock Analysis and ForecastCapital Gains Strategies & High Profit Market Growth - earlytimes.in
Chart Watch: Why Myriad Genetics Inc stock could rally in 2025Weekly Investment Report & Low Drawdown Trading Strategies - moha.gov.vn
Will Breakout in GIC Housing Finance Limited Sustain Through Next WeekCapital Gains Strategies & Free Unmatched Market Gains - earlytimes.in
Myriad Genetics, Inc. $MYGN Stake Reduced by Camber Capital Management LP - MarketBeat
Discipline and Rules-Based Execution in MYGN Response - news.stocktradersdaily.com
Why Myriad Genetics (MYGN) Stock Is Up Today - Finviz
Myriad Genetics to Showcase Advances in Hereditary Cancer and MRD Testing at 2025 San Antonio Breast Cancer Symposium - Quiver Quantitative
Myriad Genetics (NASDAQ: MYGN) spotlights MRD and MyRisk data in 8 SABCS 2025 abstracts - Stock Titan
Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q3 Earnings? - TradingView
Prudential Financial Inc. Has $1.82 Million Stock Position in Myriad Genetics, Inc. $MYGN - MarketBeat
Fisher Asset Management LLC Purchases 219,607 Shares of Myriad Genetics, Inc. $MYGN - MarketBeat
What MACD trends signal for Myriad Genetics Inc. (MYD) stock2025 Market Sentiment & Free Reliable Trade Execution Plans - Newser
Why Myriad Genetics Inc. stock appeals to analystsWeekly Trend Summary & Free Expert Approved Momentum Trade Ideas - Newser
Can Myriad Genetics Inc. stock continue upward trendMarket Trend Review & Low Drawdown Trading Techniques - Newser
Why Is Myriad (MYGN) Up 8.7% Since Last Earnings Report? - MSN
Upcoming Virtual Meeting on December 11 Hosted by Craig-Hallum f - GuruFocus
4D Path’s Physics-Inspired QPOR™ Platform Predicts Neoadjuvant Chemotherapy Response from Routine Biopsy Images in Early-Stage Triple-Negative Breast Cancer from Phase II TBCRC-030 Trial - GlobeNewswire Inc.
1 Healthcare Stock with Promising Prospects and 2 We Question - Barchart.com
How Myriad Genetics Inc. stock benefits from strong dollarTrade Risk Assessment & Low Drawdown Investment Ideas - Newser
Why Myriad Genetics (MYGN) Stock Is Trading Lower Today - Finviz
Myriad Genetics, Inc. $MYGN Stock Holdings Lifted by XTX Topco Ltd - MarketBeat
Myriad Genetics Outpaces Expectations But Faces Profit Challenges - Finimize
How Recent Developments Are Shaping the Myriad Genetics Investment Story - Yahoo Finance
UBS Initiates Coverage of Myriad Genetics (MYGN) with Neutral Recommendation - MSN
Will Myriad Genetics Inc. stock return to pre crisis levelsJuly 2025 Outlook & Breakout Confirmation Trade Signals - BỘ NỘI VỤ
Will Myriad Genetics Inc. stock attract more institutional investorsPortfolio Growth Summary & Real-Time Buy Signal Notifications - BỘ NỘI VỤ
Myriad Genetics, Inc. (MYGN) Stock Forecasts - Yahoo Finance
How Myriad Genetics achieved fast, accurate, and cost-efficient document processing using the AWS open-source Generative AI Intelligent Document Processing Accelerator - Amazon Web Services (AWS)
Earnings Recap: Can Myriad Genetics Inc. stock double in next 5 yearsTake Profit & Free Safe Entry Trade Signal Reports - BỘ NỘI VỤ
Myriad Genetics, Neogen, ICU Medical, HCA Healthcare, and Universal Health Services Stocks Trade Up, What You Need To Know - MSN
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health - The Manila Times
Clairity, Myriad Genetics, MagView partner on breast cancer risk tools By Investing.com - Investing.com Nigeria
Myriad Genetics partners to use AI to measure breast cancer risk - Seeking Alpha
Clairity, Myriad Genetics, MagView partner on breast cancer risk tools - Investing.com
Clairity, Myriad Genetics, and MagView Collaborate to Enhance Breast Cancer Risk Assessment Tool - Quiver Quantitative
Clairity, Myriad Genetics, Inc. and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health - marketscreener.com
Myriad Genetics (NASDAQ: MYGN), Clairity and MagView launch AI breast risk platform - Stock Titan
Myriad Genetics joins Forbes list of America's dream employers for 2026 - Traders Union
Myriad Genetics, Inc. (NASDAQ:MYGN) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Myriad Genetics Q3 2025 Earnings Preview - MSN
Insulet, Guardant Health, agilon health, Evolent Health, and Myriad Genetics Stocks Trade Up, What You Need To Know - Yahoo Finance
Can Myriad Genetics Inc. stock sustain market leadershipMarket Activity Report & Real-Time Volume Spike Alerts - newser.com
Is Myriad Genetics Inc. (MYD) stock nearing a technical breakout2025 Key Highlights & Detailed Earnings Play Strategies - newser.com
Will Myriad Genetics Inc. stock benefit from sector rotationJuly 2025 Technicals & Entry Point Strategy Guides - newser.com
Myriad Genetics Inc (MYGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.15%
0.39%
자본화:
|
볼륨(24시간):